Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Hepatol. 2011 Jul;55(1):207-17. doi: 10.1016/j.jhep.2010.11.012. Epub 2010 Nov 29.

Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients.

Author information

  • 1University Health Network, University of Toronto, Toronto, Canada. nazia.selzner@uhn.on.ca

Abstract

Hepatitis C virus (HCV) re-infection of the graft is universal and interferon based antiviral therapy remains at present the treatment of choice in HCV liver transplant recipients. Apart from the antiviral effects, interferon and ribavirin have both potent immunomodulatory properties resulting in a broad range of immune-related disorders including acute cellular rejection and chronic ductopenic rejection as well as de novo autoimmune hepatitis. Further complicating the picture, HCV infection per se is associated with a variety of autoimmune phenomena. We discuss here the immune-mediated complications and their relationship to chronic HCV and interferon based antiviral therapy.

Copyright © 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

PMID:
21145865
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk